LB Pharmaceuticals is a schizophrenia-focused biotech developing a new version of a decades-old medicine intended to treat schizophrenia. Its core product is a reformulated or updated iteration of that established therapy. The company has begun a Phase II schizophrenia trial. It recently closed a $75 million Series C financing. The article does not report any operating metrics such as revenue or user numbers. No investors, past rounds, founding year, or location were disclosed in the article. LB Pharmaceuticals' lead asset is LB-102 (N-methyl amisulpride), a patented benzamide designed to improve on amisulpride by enhancing blood–brain barrier permeability and potentially offering therapeutic effects at lower doses. The company plans a PET imaging study later this year and a first-in-patient, placebo-controlled Phase 2 trial of LB-102 for schizophrenia planned for mid-2021. Proceeds from the financing will support continued clinical development and exploration of a long-acting injectable version of LB-102. LB focuses on commercializing novel and improved versions of CNS treatments used extensively overseas but not approved in the U.S. The company describes its approach as low-risk/high-reward CNS drug development. LB was founded in 2015 and is based in New York City.

Total raised

$85M

Funding rounds

2

Latest round

Series C

Latest activity

Jan 2024